Single-dose pharmacokinetics of a novel oral platinum cytostatic drug([OC-6-43]-bis[acetato][1-adamantylamine]-amminedichloroplatinum [IV]) in pigs

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 26, Issue 9, 2004, Pages 679-685

  Cermanova, J ^a   Chladek, J ^a   Soval, P ^b   Kroutil, A ^b   Semerad, M ^b   Berankova, Z ^c   Siroky, P ^c   Surova, I ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Lachema sro   (Czech Republic)

^c BioTest Ltd   (Czech Republic)

Author keywords

Excretion; Pharmacokinetics; Pig; Platinum cytostatics

Indexed keywords

(OC 6-43) BIS(ACETATO)(1 ADAMANTYLAMINE)AMMINEDICHLOROPLATINUM; CYTOSTATIC AGENT; LA 12; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG URINE LEVEL; FEMALE; NONHUMAN; SINGLE DRUG DOSE; SWINE; URINARY EXCRETION;

ADMINISTRATION, ORAL; AMANTADINE; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CZECH REPUBLIC; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; FECES; FEMALE; HALF-LIFE; ORGANOPLATINUM COMPOUNDS; PLATINUM; REPRODUCIBILITY OF RESULTS; SWINE; SWINE, MINIATURE; TIME FACTORS;

EID: 11344270455     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2004.26.9.872565     Document Type: Article

References (18)

1. Lebwohl, D., Canetta, R. Clinical development of platinum complexes in cancer therapy: An historical perspective and an update. Eur J Cancer 1998, 34: 1522-34.
2. Zak, F., Turánek, J., Kroutil, A. et al. Platinum (IV) complex with adamantylamine as nonleaving amine group: Synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistam cancer cell lines. J Med Chem 2004, 47: 761-3.
3. Turánek, J., Kasná, A., Záluská, D. et al. New platinum (IV) complex with adamantylamine ligand as a promising anti-cancer drug: Comparison of in vitro cytotoxic potential towards A2780/cisR cis-platinum-resistant cell line within homologous series of platinum(IV) complexes. Anti-Cancer Drugs 2004, 15: 537-43.
4. Kelland, L.R. An update on satraplatin: The first orally available platinum anticancer drug. Expert Opin Investig Drugs 2000, 9: 1373-82.
5. Fokkema, E., Groen, H.J., Bauer, J., Uges, D.R., Weil, C., Smith, I.E. Phase II study of oral platinum drug JM2I6 as first-line treatment in patients with small-cell lung cancer. J Clin Oncol 1999, 17: 3822-7.
6. McKeage, M.J., Mistry, P., Ward, J. et al. A phase I and pharmacology study of an oral platinum complex, JM216: Dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 1995, 36: 451-8.
7. Kurata, T., Tamura, T., Sasaki, Y. et al. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine- platinum(IV) (JM216) administered once a day for five consecutive days: A phase I study. Jpn J Clin Oncol 2000, 30: 377-84.
8. Barnard, C.F.J., Raynaud, F.I., Kelland, L.R. Development of an orally active platinum anticancer drug: JM216. Top Biol Inorg Chem 1999, 1: 45-71.
9. Vouillamoz-Lorenz, S., Buclin, T., Lejeune, F., Bauer, J., Leyvraz, S., Decosterd, L.A. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days. Anticancer-Res 2003, 23(3C): 2757-65.
10. Gietema, J.A., Meinardi, M.T., Messerschmidt, J. et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 2000, 355(9209): 1075-6.
11. Hohnloser, J.H., Schierl, R., Hasford, B., Emmerich, B. Cisplatin based chemotherapy in testicalar cancer patients: Long term platinum excretion and clinical effects. Eur J Med Res 1996, 1: 509-14.
12. Graham, M.A., Lockwood, G.F., Greenslade, D., Brienza, S., Bayssas, M., Gamelin, E. Clinical pharmacokinetics of oxaliplatin: A critical review. Clin Cancer Res 2000, 6: 1205-18.
13. O'Dwyer, P.J., Stevenson, J.P., Johnson, S.W. Clinical pharmacokinetics and administration of established platinum drugs. Drugs 2000, 59 (Suppl 4): 19-27.
14. McKeage, M.J., Mistry, P., Ward, J., et al. A phase I and pharmacology study of an oral platinum complex, JM216: Dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 1995, 36: 451-8.
15. Kintzel, P.E. Anticancer drug-induced kidney disorders. Drug Saf 2001, 24(1): 19-38.
16. Nagai, N., Ogata, H. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: Importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo. Cancer Chemother Pharmacol 1997, 40: 11-8.
17. Nagai, N., Kinoshita, M., Ogata, H. et al. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. Cancer Chemother Pharmacol 1996, 39: 131-7.
18. Erdlenbruch, B., Nier, M., Kern, W., Hiddemann, W., Pekrun, A., Lakomek, M. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients. Eur J Clin Pharmacol 2001, 57: 393-402.